Biotechnology Stock Doubled This: Fund Bets 1.2M Shares
A large fund snapped up 1.2 million Vir Biotechnology shares as the stock doubled this past year. Here’s how to read ...
At retirement, target date funds typically rebalance toward conservative assets, adjusting to support withdrawals while aiming to preserve principal.
20,133 articlesA large fund snapped up 1.2 million Vir Biotechnology shares as the stock doubled this past year. Here’s how to read ...
Bitcoin sits in the upper $70,000s as investors debate whether the path to $100,000 remains open this year, supported...
Mortgage rates surge past 6.7% as bond markets wobble and geopolitics stoke inflation fears. Borrowers and lenders ad...
Four giants could join the exclusive $3 trillion club by 2027. This article breaks down the drivers, the risks, and h...
Rising gas costs push Gen Z to curb discretionary spending, nudging cosmetics brands to cut prices and rethink produc...
A clear, reader-friendly take on what the Williams-Sonoma 2026 earnings transcript reveals about growth, margins, and...
SpaceX’s IPO filing reveals a record-height valuation and a warning: Elon Musk’s media presence and cross-venture tie...
A high-stakes portfolio shuffle by a famed activist investor grabbed headlines. This piece breaks down what happened,...
Investors watch a sharpened geopolitical debate over rare earths as China tightens grip on key materials and the US a...
Choosing the right cash back card can feel overwhelming. This guide gives you a simple, actionable framework to pick ...
Investors are weighing two very different quantum paths. This guide compares D-Wave Quantum and IonQ, highlighting te...
This deep dive breaks down NextPlat's Q1 2026 earnings, translating the numbers into practical takeaways for investor...